Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Genetic Mutation Impairs Immunity in Candidiasis and Mycobacteriosis

By LabMedica International staff writers
Posted on 02 Aug 2015
Human inborn errors of immunity mediated by the cytokines interleukin-17A/F (IL-17A/F) underlie mucocutaneous candidiasis, whereas inborn errors of interferon-γ (IFN-γ) immunity underlie mycobacterial disease.

These inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis (CMC), which is characterized by chronic or recurrent infections of the skin, nails, and oral and genital mucosae by Candida albicans. More...
The inborn errors of human IFN-γ immunity underlie Mendelian susceptibility to mycobacterial disease (MSMD), a rare congenital disorder characterized by susceptibility to infections by poorly virulent intracellular pathogens such as non-tuberculosis Mycobacterium.

An international team of scientists led by those at Hiroshima University (Japan) and the Rockefeller University (New York, NY, USA) identified bi-allelic mutations in RAR-Related Orphan Receptor C (RORC), which encoded RORγ and RORγT, in seven patients from three families of diverse ethnic origins, with an unusual combination of candidiasis and mycobacteriosis. RORγT is a well-known key transcription factor of Th17 cells, which produce IL-17 and IL-22.

The team used a variety of techniques including genome-wide linkage analysis with Genome-wide Human Mapping arrays (Affymetrix; Santa Clara, CA, USA); whole-exome sequencing where genomic DNA extracted from the patients’ blood cells was sheared with a Covaris S2 Ultrasonicator (Covaris; Woburn, MA, USA); and quantitative polymerase chain reaction (qPCR) on extracted ribonucleic acid (RNA) was performed with the Light Cycler 480 Probes Master mix (Roche; Basel, Switzerland).

Severe infection episodes associated with mycobacteria were observed in patients with an unexpected phenotype compared to that observed in previous studies on Rorc-/- mice. To explain this unexpected phenotype, the scientists focused on IFN-γ immunity and identified pathological mechanisms underlying host susceptibility to mycobacteria. Leukocytes from RORC-/- patients showed impaired IFN-γ production in response to a mycobacterial challenge, and this defect is attributable to the functional impairment of γδT cells, CD4+CCR6+CXCR3+ ab Th1* cells, or both. These findings also suggested that IFN-g treatment may be beneficial for RORC-/- patients.

The authors concluded that their results demonstrate that human RORC play a surprising dual role in host defense. These findings are clinically, immunologically, and genetically robust, as they were consistent in seven patients, from three ethnic groups, homozygous for three different RORC mutations that are loss-of-function for both isoforms. Human RORC is essential not only for the development of IL-17A/F-producing lymphocytes protecting the mucocutaneous barriers against Candida, but also for the activation of IFN-γ-producing T cells, and for systemic protection against Mycobacterium. The study was published on July 9, 2015, in the journal Science.

Related Links:

Hiroshima University
Rockefeller University
Covaris




Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Alcohol Testing Device
Dräger Alcotest 7000
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.